ECEESPE2025 Poster Presentations Reproductive and Developmental Endocrinology (93 abstracts)
1University Hospital Schleswig-Holstein, Campus Lübeck, Department of Paediatrics and Adolescent Medicine, Lübeck, Germany; 2Klinikum Bremen Nord, Paediatric Endocrinology and Diabetology, Bremen, Germany; 3Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; 4University Hospital Magdeburg, Magdeburg, Germany
JOINT3160
Introduction and objective: Gonadectomy was carried out for a long time after the diagnosis of complete androgen insensitivity syndrome (CAIS). It is now recommended to leave the gonads in situ in order to guarantee endogenous hormone production. It is unclear how to best clinically monitor testicular function. The aim of the study was to investigate whether inhibin B can be used as a future follow-up parameter to screen for gonadal function in CAIS patients.
Material and Methods: A total of 57 adolescent and adult CAIS patients who presented to two DSD centers (Lübeck and Pisa) were included. Hormonal parameters were retrospectively evaluated. Ideally, we included different time points: during puberty (12-16 years), in early adulthood (17-21 years) and later adulthood (22-50 years). We evaluated the testosterone/lH ratio as a measure of Leydig cell function and the inhibin B/FSH quotient for Sertoli cell function.
Results: Testosterone levels were elevated and within the typical male reference range (6.20 ng/ml +/- 3.08). FSH values increased with age. Inhibin B levels were high and even above the male reference range (383.8 pg/ml+/- 206.5 SD). In adulthood, inhibin B levels decreased by 52.53% (P = 0.0030) and the inhibin B/FSH ratio by 75.56% (P = 0.0103).
Conclusion: Our data show that inhibin B and the inhibin B/FSH ratio is a suitable functional marker for gonadal function and in particular for Sertoli cell function. In CAIS patients from adolescence onward, these parameters may be useful to examine gonadal function and to possibly detect a loss of function that may necessitate hormone replacement therapy.